Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07180355 · ClinicalTrials.gov registry record · Phase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
A Phase 1 study of Friedreich's Ataxia (FA), sponsored by Solid Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT07180355 is a Phase 1 study of Friedreich's Ataxia (FA) that is actively recruiting participants, run by Solid Biosciences. The registered enrollment target is 10 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07180355, a Phase 1 study of Friedreich's Ataxia (FA), is actively recruiting participants, sponsored by Solid Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.
Conditions Studied
Interventions
- DRUG SGT-212
Study Locations (3)
California
- The University of California, Los Angeles (UCLA) - Los Angeles
Ohio
- The Ohio State University - Columbus
Pennsylvania
- The Children's Hospital of Philadelphia (CHOP) - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2032-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07180355
The ClinicalTrials.gov registry entry for NCT07180355 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solid Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Friedreich's Ataxia (FA) appearing as the primary indexed condition, and to 1 intervention - of which SGT-212 is the first listed.
NCT07180355 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07180355 about?
NCT07180355 is a clinical study titled "A Study of SGT-212 Gene Therapy in Friedreich's Ataxia". This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participan...
What is the current status of trial NCT07180355?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-22. Estimated completion is 2032-02-29.
What conditions does trial NCT07180355 study?
This clinical trial studies the following conditions: Friedreich's Ataxia (FA).
What interventions are being tested in trial NCT07180355?
The interventions under investigation include: SGT-212 (DRUG).
Who is sponsoring clinical trial NCT07180355?
This trial is sponsored by Solid Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07180355 being conducted?
This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.